NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® in Diverse Patient Populations Across Breast Cancer Subtypes IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 27, 2025 – Agendia®, Inc., a leader in precision Read More
Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting
FLEX Study reaches milestone of 20,000 enrolled patients, providing new insights on genomic testing across diverse patient populations IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 15, 2025 – Agendia®, Inc., announced today that Read More
Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 6, 2025 – Agendia®, Inc., Read More
Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting
Poster presentation to highlight new data on MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting. Agendia to present at Breast Fellows University Annual Meeting and host Educational Dinner Symposium Read More
MammaPrint® Reimbursement Indication Extended in Belgium
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 11, 2025 – Agendia®, Inc. announced today that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement indication for Read More
Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Sectors of Business IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 9, 2025 – Agendia®, Inc. today provided a topline review of the company’s key Read More
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrint® as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More
